The Efficacy and Safety of the 1,414 nm Nd:YAG Laser System for Alleviating Back Pain in a Lumbar Disc Patient
A 24-week, Single-center, Open-label, Clinical Study to Evaluate the Efficacy and Safety of the 1,414nm Nd:YAG Laser System Added to PEN to Further Alleviate Back Pain in a Lumbar Herniated Intervertebral Disc Patient
1 other identifier
interventional
30
0 countries
N/A
Brief Summary
This study aims to evaluate the efficacy and safety of the 1,414nm Nd:YAG laser system (ACCUPLASTI) added to Percutaneous Epidural Neuroplasty (PEN), a conventional treatment, to alleviate back pain in a lumbar herniated intervertebral disc patient.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Oct 2014
Shorter than P25 for phase_2
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2015
CompletedFirst Submitted
Initial submission to the registry
November 4, 2015
CompletedFirst Posted
Study publicly available on registry
November 5, 2015
CompletedMarch 9, 2017
April 1, 2016
1 year
November 4, 2015
March 7, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Change in the Oswestry Disability Index
Day 0, 24 weeks
Secondary Outcomes (4)
Change in the Oswestry Disability Index
Day 0, 4 weeks, 12 weeks
Change in the Visual Analogue Scale
Day 0, 4 weeks, 12 weeks, 24 weeks
12-Item Short-form Health Survey
Day 0, 4 weeks, 12 weeks, 24 weeks
Evaluation of the pain level in 4 steps of excellent, good, fair, poor, according to MacNab's Criteria
Day 0, 4 weeks, 12 weeks, 24 weeks
Study Arms (1)
1,414nm Nd:YAG laser
EXPERIMENTALIt has high absorption coefficient in water and a short pulse width.
Interventions
It has high absorption coefficient in water and a short pulse width.
Eligibility Criteria
You may qualify if:
- Adult patients 19-79 years old
- Patients with moderate disability based on the Oswestry Disability Index (ODI), among those diagnosed with a single level of unilateral herniated intervertebral disc among the 3rd-4th and 4th-5th lumbar vertebrae, or the 5th lumbar vertebra-sacral vertebra with back pain or radiating pain in the lower extremities that has been unresponsive to conservative therapy for more than six weeks
- Patients who have language skills enough to answer questionnaires
- Patients who agree to voluntarily participate in this study and to sign the Informed Consent Form, and who are able to participate for the entire period of this study
You may not qualify if:
- Patients with a multi-level, far-lateral, or bilateral lumbar herniated intervertebral disc
- Patients who use an electronic medical device for their cardiovascular system
- Patients who have spondylolisthesis in the relevant lesion
- Patients with neurological defects
- Patients who had undergone surgery on the relevant lumbar vertebra
- Patients with cauda equina syndrome
- Patients with congenital spinal deformity
- Patients with spinal fracture
- Patients with spinal infection, tumor, or other form of inflammatory spondylopathy
- Patients with coagulation disorder
- Patients with a history of malignant tumor (except those with a cured tumor and no re- occurrence for the last five years)
- Patients who had participated in another clinical study within 30 days from their screening visit
- Female patients with child-bearing potential who do not agree to use a medically acceptable contraceptive method\* for up to 24 weeks after the use of the investigational medical device during this study
- Medically acceptable contraceptive method: Condom, oral contraceptive pills taken continuously for more than three months, contraceptive injection or implants, intra- uterine contraceptive device, etc.
- Patients who are pregnant or breastfeeding
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Keung-nyun Kim, Professor
Severance Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 4, 2015
First Posted
November 5, 2015
Study Start
October 1, 2014
Primary Completion
October 1, 2015
Study Completion
October 1, 2015
Last Updated
March 9, 2017
Record last verified: 2016-04
Data Sharing
- IPD Sharing
- Will not share